Evestia Clinical Expands into U.S. with ARG Merger

• Evestia Clinical has merged with US-based Atlantic Research Group (ARG), expanding its global footprint and service offering.

• The deal more than doubles the Group’s size and introduces new therapeutic areas, including neurology and rare diseases.

Evestia Clinical has announced a merger with US-based Atlantic Research Group (ARG), forming an enlarged global CRO group with expanded capabilities across therapeutic areas and clinical development phases.

The merger, which more than doubles the size of the Group by headcount and delivery capacity, marks a strategic step in Evestia Clinical’s plan to grow through organic and acquisitive expansion. The combined entity will provide a full suite of clinical trial services from Phase 1 to Phase 3 and beyond, with strengthened capabilities in neurology, rare diseases, and late-stage development.

Headquartered in Letchworth, UK, and Charlottesville, Virginia, the new organisation will operate globally through its existing network of offices and expert partners. ARG’s clients will gain immediate access to Evestia Clinical’s international infrastructure and expanded service portfolio. All ARG employees are expected to transition to the merged organisation, with its leadership team joining the senior leadership of the enlarged Group.

“Evestia Clinical was founded to rapidly build a global specialist CRO through organic and acquisitive growth,” said Richard Barfield, Chairman of Evestia Clinical, in the press release. “The reputation of ARG’s leadership team and its high-quality CRO offering is widely recognized within the biotech and specialty pharma industry.”